Vera Therapeutics (NASDAQ:VERA) Shares Down 6.4% – Time to Sell?

Vera Therapeutics, Inc. (NASDAQ:VERA) shares traded down 6.4% on Wednesday . The company traded as low as $31.96 and last traded at $31.5260. Approximately 1,337,920 shares traded hands during trading, a decline of 15% from the average daily volume of 1,568,487 shares. The stock had previously closed at $33.67.

Key Headlines Impacting Vera Therapeutics

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: ORIGIN 3 met all prespecified endpoints. In the 428-patient final analysis, TRUTAKNA stabilized kidney function, producing a placebo-adjusted eGFR benefit of 5.6 mL/min/1.73m² at 52 weeks and a 5.0 mL/min/1.73m² annualized eGFR-slope benefit through 104 weeks. Vera Therapeutics ORIGIN 3 final analysis
• Positive Sentiment: Evidence of disease-modifying potential strengthened. Through two years, the treatment reduced the risk of a composite kidney-disease progression event by 76% versus placebo, with no TRUTAKNA patients experiencing dialysis, transplant, or death compared with eight placebo patients. Proteinuria, hematuria, and disease-related biomarkers also improved. STAT report on TRUTAKNA results
• Positive Sentiment: Regulatory and commercial catalysts are ahead. Vera plans to submit a supplemental Biologics License Application in the fourth quarter of 2026 seeking full approval, potentially in 2027. Management also reported more than 350 patient start forms during TRUTAKNA’s first ten weeks, along with early paid claims and encouraging payer policies. Yahoo Finance report on Vera shares
• Neutral Sentiment: Safety results were generally favorable, with overall adverse events and infections broadly comparable to placebo. However, TRUTAKNA remains approved under the accelerated-approval pathway, so continued approval depends on confirmation of clinical benefit and FDA review.
• Neutral Sentiment: Trading has been volatile. Shares initially rose on the trial news but later reversed, suggesting investors may be taking profits or awaiting detailed data, the supplemental BLA, and evidence that launch momentum converts into sustained revenue. Options activity also increased, reflecting heightened speculative interest. Benzinga report on VERA trading activity
• Negative Sentiment: Risks remain despite the positive trial. TRUTAKNA can increase infection risk and cause injection-site reactions, while full approval, market acceptance, payer coverage, and commercial execution are not guaranteed. Some analysts consequently maintained a more cautious view despite the clinical success. Seeking Alpha analysis of Vera Therapeutics

Analyst Ratings Changes

VERA has been the topic of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a report on Friday, July 17th. William Blair reaffirmed an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. HC Wainwright decreased their price target on Vera Therapeutics from $125.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, August 12th. Bank of America raised their price objective on Vera Therapeutics from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Finally, JPMorgan Chase & Co. increased their price objective on Vera Therapeutics from $76.00 to $83.00 and gave the stock an “overweight” rating in a report on Tuesday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $80.15.

Vera Therapeutics Stock Down 6.4%

The firm has a fifty day moving average price of $34.80 and a 200 day moving average price of $37.03. The company has a market cap of $2.27 billion, a P/E ratio of -5.38 and a beta of 0.96. The company has a quick ratio of 10.92, a current ratio of 10.92 and a debt-to-equity ratio of 0.18.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Monday, August 10th. The company reported ($1.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.58) by $0.06. During the same quarter in the prior year, the company earned ($1.20) EPS. Equities research analysts forecast that Vera Therapeutics, Inc. will post -6.44 earnings per share for the current year.

Insider Buying and Selling

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the sale, the chief executive officer directly owned 151,994 shares of the company’s stock, valued at approximately $6,429,346.20. This represents a 23.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 83,250 shares of company stock worth $3,307,800 over the last ninety days. Corporate insiders own 15.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in VERA. Engineers Gate Manager LP lifted its position in Vera Therapeutics by 1,579.2% during the second quarter. Engineers Gate Manager LP now owns 108,139 shares of the company’s stock worth $4,640,000 after purchasing an additional 101,699 shares during the period. Squarepoint Ops LLC boosted its holdings in shares of Vera Therapeutics by 569.1% during the 2nd quarter. Squarepoint Ops LLC now owns 104,937 shares of the company’s stock valued at $4,503,000 after acquiring an additional 89,253 shares in the last quarter. Arizona State Retirement System grew its holdings in shares of Vera Therapeutics by 12.3% during the second quarter. Arizona State Retirement System now owns 11,813 shares of the company’s stock worth $507,000 after purchasing an additional 1,295 shares during the last quarter. Nykredit A S acquired a new position in Vera Therapeutics in the 2nd quarter valued at approximately $97,000. Finally, Readystate Asset Management LP bought a new position in Vera Therapeutics during the 2nd quarter worth $12,663,000. 99.21% of the stock is owned by institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases. The company’s research is centered on therapies designed to address the underlying causes of autoimmune conditions rather than primarily managing their symptoms.

Vera’s leading product candidate is atacicept, an investigational biologic designed to inhibit two proteins involved in the survival and activity of antibody-producing immune cells, B-cell activating factor and a proliferation-inducing ligand.